Clinical Trial Update: PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial investigating autologous FMT to prevent dysbiosis-related complications in adults with acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• MaaT Pharma autologous fecal microbiota transplant

Snippet

Sponsor: MaaT Pharma | Conditions: Leukemia, Myeloid, Acute | Phase 1, Phase 2 | Status: COMPLETED